Literature DB >> 15931163

Characterization of the effects of adenosine receptor agonists on cerebral blood flow in uninjured and traumatically injured rat brain using continuous arterial spin-labeled magnetic resonance imaging.

Patrick M Kochanek1, Kristy S Hendrich, Edwin K Jackson, Stephen R Wisniewski, John A Melick, Paul M Shore, Keri L Janesko, Lefteris Zacharia, Chien Ho.   

Abstract

Hypoperfusion after traumatic brain injury may exacerbate damage. Adenosine, a vasodilator, regulates cerebral blood flow (CBF). Treatment with adenosine receptor agonists has shown benefit in experimental CNS trauma; however, their effects on CBF after injury remain undefined. We used magnetic resonance imaging to assess CBF in uninjured rats both early and at 24 h after intrahippocampal administration of either the nonselective adenosine receptor agonist 2-chloroadenosine (2-CA, 12 nmol) or the A(2A)-receptor agonist 2-p-(2-carboxyethyl)-phenethylamino-5'-N-ethylcarbox-amidoadenosine (CGS 21680, 6 nmol). We also assessed the effects of these agents on cerebral metabolic rate for glucose (CMRglu). We then assessed the effect of 2-CA on CBF at 3.5 to 5 h after controlled cortical impact (CCI). Injection of 2-CA into uninjured rat brain produced marked increases in CBF in ipsilateral hippocampus and cortex versus vehicle (P<0.05); CBF increases persisted even at 24 h. Measurement of hippocampal levels of 2-CA showed persistent increases to 24 h. CGS 21680 produced even more marked global increases in CBF than seen with 2-CA (2-6-fold versus vehicle, P<0.05 in 10/12 regions of interest (ROIs)). Neither agonist altered CMRglu versus vehicle. After CCI, 2-CA increased CBF in ipsilateral hippocampal and hemispheric ROIs (P<0.05 versus vehicle), but the response was attenuated at severe injury levels. We report marked increases in CBF after injection of adenosine receptor agonists into uninjured rat brain despite unaltered CMRglu. 2-Chloroadenosine produced enduring increases in CBF in uninjured brain and attenuated posttraumatic hypoperfusion. Future studies of adenosine-related therapies in CNS injury should address the role of CBF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931163     DOI: 10.1038/sj.jcbfm.9600154

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  15 in total

1.  Rheological effects of drag-reducing polymers improve cerebral blood flow and oxygenation after traumatic brain injury in rats.

Authors:  Denis E Bragin; Marina V Kameneva; Olga A Bragina; Susan Thomson; Gloria L Statom; Devon A Lara; Yirong Yang; Edwin M Nemoto
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

Review 2.  Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder.

Authors:  Robert W Van Boven; Greg S Harrington; David B Hackney; Andreas Ebel; Grant Gauger; J Douglas Bremner; Mark D'Esposito; John A Detre; E Mark Haacke; Clifford R Jack; William J Jagust; Denis Le Bihan; Chester A Mathis; Susanne Mueller; Pratik Mukherjee; Norbert Schuff; Anthony Chen; Michael W Weiner
Journal:  J Rehabil Res Dev       Date:  2009

Review 3.  The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders.

Authors:  Dietrich van Calker; Knut Biber
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

4.  2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine inhibit TNF-α and CXCL10 production from activated primary murine microglia via A2A receptors.

Authors:  Elizabeth A Newell; Jennifer L Exo; Jonathan D Verrier; Travis C Jackson; Delbert G Gillespie; Keri Janesko-Feldman; Patrick M Kochanek; Edwin K Jackson
Journal:  Brain Res       Date:  2014-11-03       Impact factor: 3.252

5.  The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.

Authors:  Sadhana Jackson; Richard T George; Martin A Lodge; Anna Piotrowski; Richard L Wahl; Sachin K Gujar; Stuart A Grossman
Journal:  J Neurooncol       Date:  2017-03-17       Impact factor: 4.130

6.  Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

Authors:  Kevin J Black; Jonathan M Koller; Meghan C Campbell; Debra A Gusnard; Stephen I Bandak
Journal:  J Neurosci       Date:  2010-12-01       Impact factor: 6.167

7.  Blood brain barrier is impermeable to solutes and permeable to water after experimental pediatric cardiac arrest.

Authors:  Erika E Tress; Robert S B Clark; Lesley M Foley; Henry Alexander; Robert W Hickey; Tomas Drabek; Patrick M Kochanek; Mioara D Manole
Journal:  Neurosci Lett       Date:  2014-06-14       Impact factor: 3.046

8.  Adenosine neuromodulation and traumatic brain injury.

Authors:  T A Lusardi
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 9.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  Adenosine A2A receptor deficiency alleviates blast-induced cognitive dysfunction.

Authors:  Ya-Lei Ning; Nan Yang; Xing Chen; Ren-Ping Xiong; Xiu-Zhu Zhang; Ping Li; Yan Zhao; Xing-Yun Chen; Ping Liu; Yan Peng; Zheng-Guo Wang; Jiang-Fan Chen; Yuan-Guo Zhou
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.